Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.6159 | 0.6076 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.6159 | 1 |
Echinococcus multilocularis | lamin | 0.0033 | 0.6159 | 0.6076 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.5949 | 0.9658 |
Onchocerca volvulus | 0.0033 | 0.6159 | 0.5 | |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.6159 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 0.6159 | 0.6076 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.6159 | 0.6076 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.6159 | 0.5815 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.6159 | 0.6076 |
Echinococcus multilocularis | musashi | 0.0033 | 0.6159 | 0.6076 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.6159 | 0.5815 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0821 | 0.1333 |
Onchocerca volvulus | 0.0033 | 0.6159 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.021 | 0.0342 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.6159 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 32.36 uM | Inhibition of jack bean urease using urea as substrate assessed as ammonia production after 15 mins by indophenol method | ChEMBL. | 24486414 |
Potency (functional) | = 1.2589 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.9362 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.581 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.